INBISTRA at SDDN 2025: Rethinking Biotech Valuation

At the 2025 Spanish Drug Discovery Network (SDDN) meeting, our CEO Ignacio Sancho-Martínez, PhD shared a sharp and timely overview on current valuation methodologies, how biotech valuations should evolve to better capture the nuances of drug discovery and what the entire early-stage ecosystem needs to do to navigate today's environment.

From the limits of generic PoS models to the importance of design-dependent evidence, optionality and structured scientific risk mapping, his talk outlined practical steps that help both companies and investors move toward more defensible and decision-ready valuations.

At INBISTRA, we apply these principles across the projects we support, translating complex R&D into clear valuation drivers, realistic development pathways and evidence-based investment decisions.

A great discussion and an important reminder that valuation is not a spreadsheet exercise. It is a strategy.